Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper

Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Downloaded from https://journals.lww.com/jpgn by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3IJrtBKuSsQVsKRVaZGM1l4DvatJ7+0OA9ytY7fNKvII= on 09/01/2020 Copyright © ESPGHAN and NASPGHAN (...) . All rights reserved. Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper Daniel H. Leung, y James E. Squires, z Ravi Jhaveri, § Nanda Kerkar, jj Chuan-Hao Lin, Parvathi Mohan, # Karen F. Murray, Regino P. Gonzalez-Peralta, yy Eve A. Roberts, and zz Shikha S. Sundaram ABSTRACT In 1989, a collaboration between the Centers for Disease Control (CDC) and a California biotechnology company identi?ed the hepatitis C virus (HCV

2020 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

2. Bulevirtide (Hepcludex) - chronic (long-term) hepatitis delta virus (HDV)

Bulevirtide (Hepcludex) - chronic (long-term) hepatitis delta virus (HDV) Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/312782/2020 EMEA/H/C/004854 Hepcludex (bulevirtide (...) ) An overview of Hepcludex and why it is authorised in the EU What is Hepcludex and what is it used for? Hepcludex is an antiviral medicine used to treat chronic (long-term) hepatitis delta virus (HDV) infection in adults with compensated liver disease (when the liver is damaged but is still able to work), when the presence of viral RNA (genetic material) has been confirmed by blood tests. HDV is an 'incomplete' virus, because it cannot replicate in cells without the help of another virus, the hepatitis B

2020 European Medicines Agency - EPARs

3. Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy

Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01757 Journal of Clinical Oncology - published online before print July 27, 2020 PMID (...) : Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update , MD, MPH 1 x Jessica P. Hwang ; , MD, MPH 2 x Jordan J. Feld ; , MD 3 x Sarah P. Hammond ; , MD, MPH 4 x Su H. Wang ; , MD, MMM 5 x Devena E. Alston-Johnson ; , JD 6 x Donna R. Cryer ; , MD 7 x Dawn L. Hershman ; , MD, MPH 8 x Andrew P. Loehrer ; , MD 9 x Anita L. Sabichi ; , MD, MACP 10 x Banu E. Symington ; , MD, MPH 11 x Norah Terrault ; , MD, MAS 12 x Melisa L. Wong ; , PhD

2020 American Society of Clinical Oncology Guidelines

4. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Full Text available with Trip Pro

Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement - The Journal of Heart and Lung Transplantation Go search , P418-432, May 01, 2020 Powered By Mendeley Share on Utilization of hepatitis C virus–infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement Saima (...) Jeffrey Teuteberg,MD Maria Crespo,MD Haifa Lyster,PharmD Laura Lourenco,PharmD Sara Machado,MD Michael Shullo,Pharm D Matthew Hartwig,MD Miranda Peraskeva,MD Cameron Wolfe,MD Kiran Khush,MD Michael Ison,MD Shelley Hall,MD Joshua Mooney,MD Steve Ivulich,PharmD Marcelo Cypel,MD Victor Pretorius,MBBS Patricia Uber,PharmD Evan Kransdorf,MD, PhD Adam Cochrane,PharmD, MPH Alan Glanville,MD Jennifer Gray,PharmD Published: March 18, 2020 DOI: The advent of therapies for successful treatment of hepatitis C

2020 International Society for Heart and Lung Transplantation

5. Hepatitis C Virus Infection in Adolescents and Adults: Screening

Hepatitis C Virus Infection in Adolescents and Adults: Screening Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation Adults aged 18 to 79 years The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years. B View the Clinical Summary in What does the USPSTF recommend? For adults aged 18 to 79 years: Grade B Screen adults for hepatitis C virus (HCV) infection. To whom does (...) evidence to determine how often to screen persons at increased risk. What are other relevant USPSTF recommendations? The USPSTF has made recommendations on screening for hepatitis B virus infection in pregnant persons, hepatitis B virus infection in adults, and HIV infection. These recommendations are available at . Where to read the full recommendation statement? Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation

2020 U.S. Preventive Services Task Force

6. Hepatitis E: symptoms, transmission, prevention, treatment

Hepatitis E: symptoms, transmission, prevention, treatment Hepatitis E: symptoms, transmission, prevention, treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis E: symptoms, transmission, prevention, treatment The symptoms, means of transmission, best means of prevention and treatment of hepatitis E. Published 1 June 2014 Last updated 16 July 2019 — From: Documents HTML Details (...) This document explains hepatitis E, describing the: symptoms means of transmission best means of prevention and treatment Published 1 June 2014 Last updated 16 July 2019 16 July 2019 Added provisional data for January to March 2019. 8 March 2019 Updated the number of hepatitis E cases in 2017 and 2018. 7 November 2018 Added provisional data for January to September 2018. 10 August 2018 Added provisional data for January to June 2018. 1 August 2018 Updated 2017 figures. 1 February 2018 Updated number

2020 Public Health England

7. Screening for Hepatitis C Virus Infection

Screening for Hepatitis C Virus Infection Screening for Hepatitis C Virus Infection | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Screening for Hepatitis C Virus Infection Practice Advisory April 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. . The on March 2, 2020. New guidance from both the CDC and the USPSTF represent a change in routine screening (...) for HCV; both organizations now recommend HCV screening for all adults, including pregnant and nonpregnant individuals. The American College of Obstetricians and Gynecologists (ACOG) is actively reviewing the new guidance from the CDC and USPSTF. Updated guidance from ACOG will be posted on ACOG’s website and published in Obstetrics & Gynecology when available. ACOG is also reviewing its current guidance on the screening and management of hepatitis for pregnant individuals in ACOG Practice Bulletin

2020 American College of Obstetricians and Gynecologists

8. AASLD Guidelines for Treatment of Chronic Hepatitis B

AASLD Guidelines for Treatment of Chronic Hepatitis B Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance Norah A. Terrault, 1 Anna S.F. Lok, 2 Brian J. McMahon, 3 Kyong-Mi Chang, 4 Jessica P. Hwang, 5 Maureen M. Jonas, 6 Robert S. Brown Jr., 7 Natalie H. Bzowej, 8 and John B. Wong 9 Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic (...) Hepatitis B (1) and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coin- fections, acute

2020 American Association for the Study of Liver Diseases

9. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US and a leading cause of complications from chronic liver disease. HCV is associated with more deaths than the top 60 other reportable infectious diseases combined, including HIV. Cases of acute HCV infection have increased approximately 3.8-fold over the last decade because of increasing

2020 JAMA

10. Givosiran (Givlaari) - acute hepatic porphyria

Givosiran (Givlaari) - acute hepatic porphyria Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/62114/2020 EMEA/H/C/004775 Givlaari (givosiran) An overview of Givlaari and why (...) it is authorised in the EU What is Givlaari and what is it used for? Givlaari is a medicine for treating acute hepatic porphyria in patients aged 12 years or over. Acute hepatic porphyria is a rare genetic condition in which the liver cannot properly produce a substance called haem. As a result, substances used to make haem build up in the body, causing attacks of severe abdominal pain, vomiting and nervous system disorders. Acute hepatic porphyria is rare, and Givlaari was designated an ‘orphan medicine

2020 European Medicines Agency - EPARs

11. Toolkit to support the generation of robust estimates of hepatitis C prevalence

Toolkit to support the generation of robust estimates of hepatitis C prevalence TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project www.ecdc.europa.euECDC TECHNICAL REPORT Technical protocol for hepatitis C prevalence surveys in the general population SPHERE-C Project ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Erika Duffell and Andrew Amato-Gauci, and produced (...) : European Centre for Disease Prevention and Control. Technical protocol for hepatitis C prevalence surveys in the general population. Stockholm: ECDC; 2020. Stockholm, February 2020 ISBN 978-92-9498-423-4 doi: 10.2900/30190 Catalogue number TQ-03-19-928-EN-N © European Centre for Disease Prevention and Control, 2019 Cover picture: © Science Photo Reproduction is authorised, provided the source is acknowledged. For any use or reproduction of photos or other material that is not under the EU copyright

2020 European Centre for Disease Prevention and Control - Technical Guidance

12. Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility (Abstract)

Phlebotomy resulting in controlled hypovolaemia to prevent blood loss in major hepatic resections (PRICE-1): a pilot randomized clinical trial for feasibility Major liver resection is associated with blood loss and transfusion. Observational data suggest that hypovolaemic phlebotomy can reduce these risks. This feasibility RCT compared hypovolaemic phlebotomy with the standard of care, to inform a future multicentre trial.Patients undergoing major liver resections were enrolled between June

2020 EvidenceUpdates

13. Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. Full Text available with Trip Pro

Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care. To evaluate the effectiveness and cost effectiveness of a complex intervention in primary care that aims to increase uptake of hepatitis C virus (HCV) case finding and treatment.Pragmatic, two armed, practice level, cluster randomised controlled trial and economic evaluation.45 general practices in South West England (22 randomised

2020 BMJ

14. Disorders of the Hepatic and Mesenteric Circulation Full Text available with Trip Pro

Disorders of the Hepatic and Mesenteric Circulation ACG Clinical Guideline: Disorders of the Hepatic and Mesente... : American Journal of Gastroenterology ')} You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800 (...) Abstract Disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries have important clinical consequences and may lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma. Although literature in the field of vascular liver disorders is scant, these disorders are common in clinical practice, and general practitioners, gastroenterologists, and hepatologists may benefit from expert guidance

2020 American College of Gastroenterology

15. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Full Text available with Trip Pro

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We performed a randomized trial of the safety and efficacy of 12 and 16 weeks of G/P, with or without

2020 EvidenceUpdates

16. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

17. Givosiran (Givlaari) - acute hepatic porphyria

Givosiran (Givlaari) - acute hepatic porphyria Drug Approval Package: GIVLAARI (givosiran)Injection U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GIVLAARI (givosiran)Injection Company: Alnylam Pharmaceuticals Inc. Application Number: 212194 Approval Date: 11/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

18. Hepatitis B

Hepatitis B Hepatitis B | Topics A to Z | CKS | NICE Search CKS… Menu Hepatitis B Hepatitis B Last revised in November 2019 Hepatitis B is an infectious disease of the liver caused by the hepatitis B virus. Diagnosis Management Prescribing information Background information Hepatitis B: Summary Hepatitis B is an infectious disease of the liver caused by the hepatitis B virus. The prevalence of people with antibodies to hepatitis B core antigen (anti-HBc) — a marker of current or previous (...) infection (seroprevalence) — is 1–2% in the UK. In parts of China and South Korea, the seroprevalence is 96%. In the UK, most new infections are acquired in adulthood. The source of infection is most commonly via sexual contact or sharing equipment for injecting drugs with other people with chronic hepatitis B. Acute hepatitis B symptoms and jaundice generally last for 1–3 months. Hepatitis B surface antigen (HBsAg) is cleared in around 95% of immunocompetent adults. Fulminant hepatitis occurs in less

2020 NICE Clinical Knowledge Summaries

19. Hepatitis A: What issues should I consider before prescribing analgesia?

Hepatitis A: What issues should I consider before prescribing analgesia? Analgesia | Prescribing information | Hepatitis A | CKS | NICE Search CKS… Menu Analgesia Hepatitis A: What issues should I consider before prescribing analgesia? Last revised in October 2019 What issues should I consider before prescribing analgesia? For prescribing information on paracetamol, ibuprofen, and codeine, see the CKS topic on . For more detailed prescribing information on nonsteroidal anti-inflammatory drugs

2020 NICE Clinical Knowledge Summaries

20. Hepatitis A: What issues should I consider before giving hepatitis A vaccine?

Hepatitis A: What issues should I consider before giving hepatitis A vaccine? Hepatitis A vaccine | Prescribing information | Hepatitis A | CKS | NICE Search CKS… Menu Hepatitis A vaccine Hepatitis A: What issues should I consider before giving hepatitis A vaccine? Last revised in October 2019 What issues should I consider before giving hepatitis A vaccine? What types of hepatitis A vaccine are available? There are several hepatitis A vaccines that are licensed for use in the UK. All (...) are inactivated, and prepared from different strains of the hepatitis A virus: Avaxim ® Havrix Monodose ® Havrix Junior Monodose ® Vaqta ® Vaqta Paediatric ® There are also combined hepatitis A and B vaccines: Twinrix ® (adult and paediatric formulations) Ambirix ® (paediatric formulation) A combined hepatitis A and typhoid vaccine (ViATIM ® ) is also available. [ ; ] What is the immunization schedule for the hepatitis A vaccine? The hepatitis A monovalent vaccine is given as two doses, 6–12 months apart

2020 NICE Clinical Knowledge Summaries